SOLIRIS is the first and only FDA-approved treatment for PNH
PNH is a rare blood disorder in which red blood cells are chronically destroyed
by a process called "hemolysis." The ongoing destruction of red blood cells
leads to the signs and symptoms of PNH such as anemia, often requiring
transfusions, disabling fatigue, recurrent pain, impaired quality of life,
shortness of breath, and blood clots.
SOLIRIS® (eculizumab) works by targeting and reducing hemolysis — the underlying
cause of PNH symptoms. By reducing red blood cell destruction, or hemolysis,
treatment with SOLIRIS improves anemia, fatigue and other symptoms and helps PNH
patients enjoy a better quality of life. In clinical trials, patients
experienced fewer blood clots with SOLIRIS treatment as compared to the same
period of time prior to treatment.
